T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

Detalles Bibliográficos
Autores principales: Diefenbach, Catherine, Jegede, Opeyemi, Ambinder, Richard, Cohen, Jonathon, Robertson, Michael, David, Kevin, Advani, Ranjana, Fenske, Timothy, Barta, Stefan, Palmisiano, Neil, Svoboda, Jakub, Morgan, David, Karmali, Reem, Kahl, Brad, Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Relapsed/Refractory
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621511/
http://dx.doi.org/10.1097/01.HS9.0000890968.53519.f4
Descripción
Sumario:

Ejemplares similares